CELLZOME
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma. CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg.
CELLZOME
Social Links:
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2000-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.cellzome.com
Total Employee:
51+
Status:
Closed
Contact:
+499193153362
Total Funding:
69.29 M USD
Technology used in webpage:
CSC Global DNS
Current Advisors List
Current Employees Featured
Founder
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CellZome
Atlas Venture
Atlas Venture investment in Series C - CellZome
Biofrontier Partners
Biofrontier Partners investment in Series C - CellZome
Schroder Ventures
Schroder Ventures investment in Series C - CellZome
Advent International
Advent International investment in Series C - CellZome
Societe Generale Asset Management
Societe Generale Asset Management investment in Series C - CellZome
Atlas Venture
Atlas Venture investment in Series B - CellZome
Advent International
Advent International investment in Series B - CellZome
Schroders
Schroders investment in Series B - CellZome
Index Ventures
Index Ventures investment in Series B - CellZome
Official Site Inspections
http://www.cellzome.com
- Host name: ns1.cellzome.de
- IP address: 195.37.234.227
- Location: Friedberg Germany
- Latitude: 50.3374
- Longitude: 8.7559
- Timezone: Europe/Berlin
- Postal: 61169
More informations about "CellZome"
CellZome - Crunchbase Company Profile & Funding
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases.See details»
Cellzome GmbH, a GSK company - Life-Sciences-Europe.com
Sep 14, 2012 Advertisement. Organisation › Details Cellzome GmbH, a GSK company. Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and …See details»
Cellzome - Products, Competitors, Financials, Employees, …
Cellzome. Frequently Asked Questions (FAQ). When was Cellzome founded? Cellzome was founded in 2000. Where is Cellzome's headquarters? Cellzome's headquarters is located at …See details»
CellZyme
Building a drug discovery platform for challenging drug targetsSee details»
Cellzome - LinkedIn
Cellzome | 1,615 followers on LinkedIn. Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of ...See details»
Cellzome - Company Profile - Tracxn
Cellzome - Small-molecule kinase targeted drugs to treat inflammatory diseases. Acquired by GSK. Raised a total funding of $78.1M over 3 rounds from 12 investors. Cellzome has 3065 …See details»
CellZome - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Cellzome Company Profile 2024: Valuation, Investors ... - PitchBook
Cellzome General Information Description. Developer of kinase-targeted drugs developed for the treatment of inflammatory diseases. The company develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma.See details»
Cellzome (Group) - life-sciences-europe.com
Upcoming Events. Life Science Start-up Day 2024 Göttingen; Pittcon 2024 San Diego; BIO CEO & Investor Conference 2024 New York; CAR-TCR Europe 2024 LondonSee details»
GlaxoSmithKline to fully acquire Cellzome for £61 million - GSK
Issued: London UK. GSK to further expand its platform technology expertise with acquisition of chemical proteomics company. GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US $99 million) in …See details»
GSK to acquire Cellzome for $99 million | Drug Discovery News
May 17, 2012 Zacks Investment Research acknowledged the likelihood that adding Cellzome's proteomics technologies would enable better analysis of a drug's efficacy and safetyprofile, thus reducing the number of discontinued candidates in developmentphases for GSK, but the prospect of folding Cellzome into GSK's R&D organization and spinning off a new ...See details»
Cellzome (Group) - life-sciences-europe.com
Upcoming Events. Chardan Genetic Medicines Conference 2023 New York; BioCentury-BayHelix East-West Biopharma Summit 2023 Boston; BioFuture 2023 New YorkSee details»
Cellzome: 20 years of innovation - YouTube
Feb 15, 2023 For more than 20 years, Cellzome is a proud member of an innovative ecosystem that enables biotech research and development "made in Germany". For 10 years, ...See details»
Cellzome - VentureRadar
Similar Companies: QAtor Denmark Privately Held QAtor is a global software firm specialising in compliance and Quality Assurance software for the Life Sciences Industry. The company has …See details»
Cellzome: Biotechnological Research "Made in Germany" for a …
Cellzome uses its innovative technologies to understand the molecular mechanisms of disease development and drugs. Omics technologies (genomics, transcriptom...See details»
GSK spends £61 million to take full control of Cellzome
May 17, 2020 The UK’s biggest pharmaceutical manufacturer, GlaxoSmithKline (GSK), has announced it will be spending £61 million to take full control of Cellzome.. GSK currently owns …See details»
Cellzome Genetics & Genomics News | GenomeWeb
NEW YORK (GenomeWeb) – A team led by researchers at Cellzome, a part of GlaxoSmithKline's R&D division, has developed a thermal profiling-based method for identifying protein drug …See details»
Cellzome Announces Achievement of First Milestone in …
Dec 11, 2008 Cellzome Inc. announced that it has successfully achieved the first milestone in the strategic alliance with GlaxoSmithKline (GSK) established earlier this year, triggering …See details»
Cellular Organizational Structure - FourWeekMBA
Jun 25, 2024 A Cellular Organizational Structure is a model of organizational design characterized by the division of an organization into smaller, self-contained units or cells. Each …See details»
GlaxoSmithKline Signs Up to $1.5 Billion Drug Deal with Cellzome
Sep 10, 2008 Under the terms of the agreement, Cellzome will receive upfront payments of GBP14.4 million comprised of both cash and equity. Cellzome is eligible for up to GBP118 million per program in ...See details»